Positive Phase 2 results of NovaDigm TX’s NDV-3A vaccine published in Clinical Infectious Diseases
BOSTON - April 25, 2018 - NovaDigm Therapeutics, a company developing innovative immuno-therapeutics and preventative vaccines for fungal and bacterial infections, today announced the publication...






